Genentech's Lucentis Heads to FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Genentech is touting the breadth and quality of data for the macular degeneration agent, including two Phase III trials and results showing superiority to Novartis/QLT's Visudyne.
You may also be interested in...
Genentech Submits Additional Lucentis Data To FDA
Label for Lucentis, pending for wet age-related macular degeneration, could include data from a Phase IIIb study supporting continuous treatment.
Genentech Submits Additional Lucentis Data To FDA
Label for Lucentis, pending for wet age-related macular degeneration, could include data from a Phase IIIb study supporting continuous treatment.
Lucentis Receives Priority Review
The BLA for Genentech's wet age-related macular degeneration therapy Lucentis (ranibizumab) has been granted six-month priority review by FDA. The user fee date has been set for June 29, 2006